Beck Capital Management’s BioNTech BNTX Stock Holding History

Beck Capital Management’s Portfolio BNTX Stock Details BNTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-18,367	Closed	-$4.11M	–	139
2021 Q2	$4.11M	Buy	+18,367	New	+$3.46M	1.38%	20

Other funds holding BNTX

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Fosun International Hong Kong, China $446M AUM 13.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Pendal Group Sydney, Australia $11.6B AUM 12.87% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Coatue Management New York $48.6B AUM 94.27% 1-Year Est. Return

Beck Capital Management's BNTX Position: Q3 2021 in Review

Beck Capital Management sold out of BioNTech (BNTX) in Q3 2021, closing a stake of 18,367 shares — an estimated $4.11M sold.

Beck Capital Management first reported a position in BNTX in Q2 2021 and held it in 1 quarter. The position peaked at $4.11M in Q2 2021. 336 funds tracked by Wall St. Rank hold BNTX as of Q3 2021.

Beck Capital Management reported no remaining BioNTech position as of Q3 2021 after selling out during the quarter.
Beck Capital Management sold 18,367 BioNTech shares in Q3 2021, an estimated $4.11M.
Beck Capital Management first reported a position in BioNTech in Q2 2021 and held it in 1 quarter.
Beck Capital Management's BioNTech position peaked at $4.11M in Q2 2021.
336 funds tracked by Wall St. Rank held BioNTech as of Q3 2021.

Based on Beck Capital Management's 13F filing for Q3 2021, filed 12 Nov 2021.